



**Extraordinary Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
16 December 2021
Virtual meeting
Agenda**

Thursday, 16 December 2021

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
12:00	Opening and welcome Opening: Welcome: A. CRAVIOTO. SAGE Chair. 5 min.	Opening of the plenary meeting	5 min.
12:05	Introduction and objective setting Introduction to the. K. O'BRIEN. Director Immunization Vaccines and Biologicals. WHO. 5 min. Objective setting. H. NOHYNEK. SAGE Working Group Chair. 5 min.	FOR INFORMATION	10 min.
12:15	Novavax recommendations Vaccine safety and efficacy data emerging on the Novavax COVID-19 vaccine clinical trials (phase 1-3 trial results). Risk management plans and other implementation considerations. COMPANY PRESENTATION. 30 min. Questions. 30 min.	FOR RECOMMENDATION Presentation of clinical data from phase 1, 2 and 3 studies on safety, immunogenicity and efficacy. Outline of ongoing and planned studies.	60 min.
13:15	Break	Break	15 min.
13:30	Novavax recommendations, continued. Evidence assessment and GRADEing. M. MARTI./E. PARKER PWHO. 15 min. Presentation of draft recommendations, including discussion. H. NOHYNEK. SAGE Working Group chair. 45 min.	FOR RECOMMENDATION Presentation of the assessment of the SAGE working group on the available evidence and the strength of evidence on the questions of the evidence to recommendation tables. Based on the presented evidence, presentation of draft recommendations on the use of the Novavax vaccine against COVID-19.	60 min.
14:30	Concluding remarks Concluding remarks. H. NOHYNEK and A. CRAVIOTO. SAGE Working Group Chair and Chair of SAGE. 5 min.	FOR INFORMATION	5 min.
14:35	End of the meeting		